Intellia Therapeutics Inc... (NTLA)
Intellia Therapeutics Statistics
Share Statistics
Intellia Therapeutics has 103.58M shares outstanding. The number of shares has increased by 7.3% in one year.
| 103.58M |
| 7.3% |
| 1.64% |
| 98.29% |
| n/a |
| 560 |
| 0.01% |
Short Selling Information
The latest short interest is 30.7M, so 29.64% of the outstanding shares have been sold short.
| 30.7M |
| 29.64% |
| 33.74% |
| 8.69 |
Valuation Ratios
The PE ratio is -2.22 and the forward PE ratio is -1.94. Intellia Therapeutics's PEG ratio is 0.71.
| -2.22 |
| -1.94 |
| 19.91 |
| 0.4 |
| 1.32 |
| -3.25 |
| 0.71 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intellia Therapeutics.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.24.
| 5.77 |
| 5.77 |
| 0.24 |
| -0.4 |
| -0.59 |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $143,615.38 |
| $-1,287,893.3 |
| 403 |
| 0.05 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by -64.54% in the last 52 weeks. The beta is 2.13, so Intellia Therapeutics's price volatility has been higher than the market average.
| 2.13 |
| -64.54% |
| 7.93 |
| 13.05 |
| 49.11 |
| 3,998,796 |
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 57.88M and earned -519.02M in profits. Earnings per share was -5.25.
| 57.88M |
| 47.59M |
| -534.26M |
| -519.02M |
| -523.98M |
| -534.26M |
| -5.25 |
Balance Sheet
The company has 189.18M in cash and 210.2M in debt, giving a net cash position of -21.02M.
| 189.18M |
| 210.2M |
| -21.02M |
| -2.18B |
| 986.16M |
| 438.8M |
Cash Flow
In the last 12 months, operating cash flow was -348.88M and capital expenditures -5.78M, giving a free cash flow of -354.66M.
| -348.88M |
| -5.78M |
| -354.66M |
| -3.59 |
Margins
Gross margin is 82.23%, with operating and profit margins of -923.1% and -896.77%.
| 82.23% |
| -923.1% |
| -896.77% |
| -896.77% |
| -905.33% |
| -923.1% |
| -612.78% |
Dividends & Yields
NTLA does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for NTLA is $40.5, which is 402.5% higher than the current price. The consensus rating is "Buy".
| $40.5 |
| 402.5% |
| Buy |
| 20 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| -2.27 |
| 2 |